Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Roche Ends Polyphor Antibiotics Pact
by Lisa M. Jarvis
December 7, 2015
| A version of this story appeared in
Volume 93, Issue 48
Roche has dissolved an antibiotics pact with the Swiss biotech firm Polyphor. The companies joined forces in 2013 to develop POL7080, a macrocycle antibiotic currently in Phase II tests to treat hospital-acquired bacterial infections caused by Pseudomonas aeruginosa. Polyphor says it plans to continue the trials. The partnership was one of the first established by Roche as it reentered the antibiotics field; it has since sealed partnerships with Meiji Seika Pharma, Discuva, and Spero Therapeutics.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter